Generali Investments Management Co LLC Takes Position in Pfizer Inc. (NYSE:PFE)

Generali Investments Management Co LLC purchased a new stake in shares of Pfizer Inc. (NYSE:PFE) during the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor purchased 24,722 shares of the biopharmaceutical company’s stock, valued at approximately $656,000.

Several other hedge funds and other institutional investors have also recently modified their holdings of PFE. Retirement Wealth Solutions LLC bought a new stake in shares of Pfizer during the fourth quarter valued at about $26,000. Rialto Wealth Management LLC bought a new stake in shares of Pfizer during the fourth quarter valued at about $26,000. Kohmann Bosshard Financial Services LLC bought a new stake in shares of Pfizer during the fourth quarter valued at about $28,000. Noble Wealth Management PBC bought a new stake in shares of Pfizer during the fourth quarter valued at about $31,000. Finally, Curio Wealth LLC purchased a new position in shares of Pfizer during the fourth quarter worth about $32,000. 68.36% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several brokerages have recently commented on PFE. Truist Financial cut their price objective on Pfizer from $36.00 to $32.00 and set a “buy” rating for the company in a report on Wednesday, December 18th. Citigroup cut their price objective on Pfizer from $30.00 to $29.00 and set a “neutral” rating for the company in a report on Tuesday, January 28th. Hsbc Global Res raised Pfizer to a “strong-buy” rating in a report on Monday, March 10th. StockNews.com lowered Pfizer from a “strong-buy” rating to a “buy” rating in a report on Wednesday, November 20th. Finally, Bank of America reissued a “neutral” rating and set a $29.00 price objective on shares of Pfizer in a report on Tuesday, December 10th. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating, six have issued a buy rating and three have assigned a strong buy rating to the stock. According to data from MarketBeat.com, Pfizer has an average rating of “Moderate Buy” and an average price target of $31.92.

Insider Activity

In related news, Director Ronald E. Blaylock acquired 19,457 shares of the company’s stock in a transaction dated Thursday, February 13th. The stock was purchased at an average price of $25.65 per share, with a total value of $499,072.05. Following the completion of the purchase, the director now owns 27,707 shares in the company, valued at $710,684.55. This trade represents a 235.84 % increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 0.06% of the company’s stock.

Pfizer Stock Performance

NYSE:PFE opened at $26.31 on Wednesday. The firm has a market cap of $149.09 billion, a PE ratio of 18.66, a price-to-earnings-growth ratio of 0.64 and a beta of 0.61. Pfizer Inc. has a fifty-two week low of $24.48 and a fifty-two week high of $31.54. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00. The business has a 50 day moving average price of $26.21 and a 200-day moving average price of $27.09.

Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share for the quarter, beating analysts’ consensus estimates of $0.48 by $0.15. The firm had revenue of $17.76 billion during the quarter, compared to analyst estimates of $17.26 billion. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The business’s quarterly revenue was up 24.7% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.10 earnings per share. Equities research analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.